- Single, low-dose administration of 무료 바카라 게임 led to a 91% reduction in the annualized anti-VEGF injections in Cohort 1
- A favorable safety profile was observed in Cohort 1, with no serious adverse events (SAEs) or dose-limiting toxicities (DLTs)
- Vision (BCVA) and retinal thickness (CST) remained stable through 36 weeks, demonstrating durability of treatment effect
[by Ji, Yong Jun] Neuracle Genetics Inc., a clinical-stage biotechnology company developing adeno-associated virus (AAV) gene therapies, announced on September 15 positive interim results from the low-dose cohort of its Phase 1/2a SENSE study of NG101. The data, presented on September 12, 2025, at the 58th Annual Scientific Meeting of The Retina Society in Chicago, show that a single subretinal administration of NG101 in patients with wet age-related macular degeneration (wet AMD) resulted in a significant reduction in treatment burden and was well-tolerated. The presentation was delivered by Dr. Christopher Riemann of the Cincinnati Eye Institute.
The SENSE study (NCT05984927) is a multicenter, open-label, dose-escalation trial evaluating the safety, tolerability, and preliminary efficacy of 무료 바카라 게임. The data reported are from the low-dose cohort (1x109 vg/eye; n=6). Analysis showed patients experienced a 91% reduction in the annualized anti-VEGF injections. Prior to the study, these patients required an annual average of 9.8 anti-VEGF injections. Furthermore, Best Corrected Visual Acuity (BCVA) and Central Subfield Thickness (CST) remained stable through 36 weeks of follow-up.
무료 바카라 게임 continues to be well-tolerated, with no 무료 바카라 게임-related serious adverse events (SAEs), dose-limiting toxicities (DLTs), or clinically significant retinal pigment epithelium (RPE) changes observed, other than mild or transient adverse events.
“무료 바카라 게임 was able to dramatically reduce the treatment burden of anti-VEGF injections with a single low-dose administration while maintaining stable vision and anatomical outcomes,” said Dr. Riemann. “With this favorable safety profile, we look forward to seeing the data from the medium- and high-dose cohorts and long-term follow-up.”
Neuracle Genetics highlighted that 무료 바카라 게임 demonstrated the therapeutic effect at a dose that is a fraction of other investigational AAV gene therapies for wet AMD. A lower effective dose may lead to an improved safety profile and lower treatment costs, potentially strengthening the competitive position of 무료 바카라 게임.
“We are thrilled that 무료 바카라 게임 has demonstrated clear efficacy and safety at this low dose,” said Jongmook Kim, CEO of Neuracle Genetics. “We will continue to validate the safety and durability of 무료 바카라 게임 in the medium- and high-dose cohorts to determine the optimal dose as we prepare to advance into a global Phase 2b trial.”
The company had completed the enrollment of Cohort 2 (3x109 vg/eye; n=6) and is currently evaluating safety and efficacy while actively enrolling Cohort 3 (8x109 vg/eye; n=6).